Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cancer Related Cognitive Decline × Carboplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 679 Lung Neoplasms 295 Ovarian Neoplasms 286 Breast Neoplasms 241 Fallopian Tube Neoplasms 144 Small Cell Lung Carcinoma 124 Triple Negative Breast Neoplasms 123 Neoplasms 120 Squamous Cell Carcinoma of Head and Neck 109 Carcinoma, Ovarian Epithelial 107 Neoplasm Metastasis 74 Head and Neck Neoplasms 69 Endometrial Neoplasms 65 Esophageal Neoplasms 60 Uterine Cervical Neoplasms 59 Adenocarcinoma of Lung 59 Central Nervous System Neoplasms 46 Brain Neoplasms 46 Recurrence 44 Carcinoma 43 Prostatic Neoplasms 42 Neuroblastoma 42 Lymphoma, Large B-Cell, Diffuse 42 Parkinson Disease 4, Autosomal Dominant Lewy Body 39 Urinary Bladder Neoplasms 37 Esophageal Squamous Cell Carcinoma 36 Lymphoma 34 Carcinoma, Squamous Cell 32 Stomach Neoplasms 30 Melanoma 29

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡